2025 Global Antibody Drug Conjugates Contract Manufacturing Revenue Opportunities Report
Description
The 2025 Global Antibody Drug Conjugates Contract Manufacturing Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibody Drug Conjugates Contract Manufacturing by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the global Antibody Drug Conjugates (ADC) contract manufacturing market are Lonza Group, WuXi Biologics, Catalent, Inc., and Samsung Biologics. These companies hold significant market shares and provide comprehensive services spanning from early-stage development to commercial-scale manufacturing of ADCs. Lonza Group is recognized for its advanced biopharmaceutical manufacturing platforms, while WuXi Biologics, with facilities in Asia (notably Shanghai, Wuxi, and Hangzhou), offers state-of-the-art cGMP ADC production with large-scale bioreactor capacities. Catalent and Samsung Biologics also have strong presences, leveraging cutting-edge bioprocessing technologies and regulatory expertise to meet growing demand for targeted cancer therapies.
These companies drive market growth through strategic expansions and investments. For example, WuXi AppTec expanded its R&D and manufacturing footprint in Singapore to enhance peptide, small molecule, and conjugate capabilities. Catalent and Lonza have invested in next-generation ADC technologies and manufacturing efficiencies. The market is also fueled by rising global cancer incidence, outsourcing trends from pharma companies to specialized CMOs, and innovations in linker and payload technologies, which these companies support with robust regulatory compliance and extensive clinical supply experience. Their cooperative initiatives and technological advancements position them as leaders in meeting the complex and stringent demands of ADC manufacturing worldwide.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibody Drug Conjugates Contract Manufacturing by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the global Antibody Drug Conjugates (ADC) contract manufacturing market are Lonza Group, WuXi Biologics, Catalent, Inc., and Samsung Biologics. These companies hold significant market shares and provide comprehensive services spanning from early-stage development to commercial-scale manufacturing of ADCs. Lonza Group is recognized for its advanced biopharmaceutical manufacturing platforms, while WuXi Biologics, with facilities in Asia (notably Shanghai, Wuxi, and Hangzhou), offers state-of-the-art cGMP ADC production with large-scale bioreactor capacities. Catalent and Samsung Biologics also have strong presences, leveraging cutting-edge bioprocessing technologies and regulatory expertise to meet growing demand for targeted cancer therapies.
These companies drive market growth through strategic expansions and investments. For example, WuXi AppTec expanded its R&D and manufacturing footprint in Singapore to enhance peptide, small molecule, and conjugate capabilities. Catalent and Lonza have invested in next-generation ADC technologies and manufacturing efficiencies. The market is also fueled by rising global cancer incidence, outsourcing trends from pharma companies to specialized CMOs, and innovations in linker and payload technologies, which these companies support with robust regulatory compliance and extensive clinical supply experience. Their cooperative initiatives and technological advancements position them as leaders in meeting the complex and stringent demands of ADC manufacturing worldwide.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
